{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-037497","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.878586+00:00","generated_at":"2026-05-15T08:11:15.603205+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review","bullets":["Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.","Operating expenses fell to $5.8M in 2025 from $10.8M in 2024.","Cash and cash equivalents $762k as of Dec 31, 2025; $2.0M in digital asset treasury.","Board initiated evaluation of strategic alternatives on March 25, 2026; no timetable set.","TAEUS Liver feasibility study showed r=0.89 correlation with MRI-PDFF for liver fat."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-037497","json":"https://secwatch.observer/filing/0001213900-26-037497.json","markdown":"https://secwatch.observer/filing/0001213900-26-037497.md","text":"https://secwatch.observer/filing/0001213900-26-037497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/0001213900-26-037497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/ea0284372-8k_endralife.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:11:15.603205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bb4eb053bad71143bb9a8f4745cf0824c4d06ed","claim":"ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2025 results: net income net loss of $3.2 million.","evidence_excerpt":"in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024. 2025 Financial Results During 2025 the Company benefitted from actions taken throughout 2024 to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/0001213900-26-037497-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2025"},{"label":"Net income","value":"net loss of $3.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}